Welichem Biotech Inc. is a clinical stage biotech company engaging in the discovery and development of novel small molecule therapeutics for unmet medical needs. Before 2012, the Company was dedicated to research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives. WBI-1001 was a novel anti-inflammatory agent developed by the Company as a topical treatment for inflammatory skin diseases such as psoriasis and atopic dermatitis. Four clinical studies were completed by the Company using WBI-1001 creams for the treatment of atopic dermatitis and psoriasis. In July 2012, the WBI- 1001 technology was acquired by Stiefel, A Glaxo Group Limited (GSK) company, for further development, regulatory approval, and commercialization.

Welichem's core strength has been early stage drug discovery and development since its incorporation. In the past, the Company has been successful in advancing drug compounds to clinical proof of concept stages and partnering with a pharmaceutical company to maximize the value of the technology. Our experience allows us to move rapidly from early stage drug discovery and development to clinical proof of concept and collaborate with strategic partners for later stage of commercialization of our drug candidates.